Search Results

You are looking at 111 - 120 of 551 items for :

  • neuroendocrine cancer x
  • All content x
Clear All
Free access

Massimo Milione, Patrick Maisonneuve, Alessio Pellegrinelli, Federica Grillo, Luca Albarello, Paola Spaggiari, Alessandro Vanoli, Giovanna Tagliabue, Eleonora Pisa, Luca Messerini, Giovanni Centonze, Frediano Inzani, Aldo Scarpa, Mauro Papotti, Marco Volante, Fausto Sessa, Nicola Fazio, Giancarlo Pruneri, Guido Rindi, Enrico Solcia, Stefano La Rosa, and Carlo Capella

Introduction The coexistence of neuroendocrine and non-neuroendocrine components in the same neoplasm is a rare but well-known phenomenon in digestive system tumors. The 2010 World Health Organization (WHO) classification of tumors of the

Free access

Michael Höpfner, Viola Baradari, Alexander Huether, Christof Schöfl, and Hans Scherübl

cancers is not well controlled by either biotherapy or chemotherapy. Thus, therapeutic options to inhibit the growth and spread of neuroendocrine gastrointestinal tumours (NET) are still unsatisfactory. In the light of the particular biology of NET

Free access

Renea A Taylor, Roxanne Toivanen, and Gail P Risbridger

have the capacity to become tumorigenic ( Visvader 2009 ). This may be similar in prostate cancer, but our understanding is not so advanced as in breast cancer and based on the occurrence of luminal or neuroendocrine tumors, subclassifications of tumor

Open access

Anna Koumarianou, Stavroula Antoniou, George Kanakis, Nikolaos Economopoulos, Dimitra Rontogianni, Anastasios Ntavatzikos, Nikolaos Tsavaris, Dimitrios Pectasides, George Dimitriadis, and Gregory Kaltsas

Kindmark H Dunder K Kozlovacki G Orlefors H Sigurd M 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors . Clinical Cancer Research 13 2986 – 2991 . doi:10.1158/1078-0432.CCR-06

Free access

Luisella Righi, Marco Volante, Ida Rapa, Veronica Tavaglione, Frediano Inzani, Giuseppe Pelosi, and Mauro Papotti

Nicklee T Ho J 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas . British Journal of Cancer 95 1148 – 1154 doi:10.1038/sj.bjc.6603419 . Duran I Salazar R Casanovas O Arrazubi V

Free access

Mohid S Khan and Martyn E Caplin

Sabourin JC De BT Mitry E Schlumberger M Rougier P 2001 Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours . European Journal of Cancer 37 1014 – 1019 . doi:10.1016/S0959

Open access

Tobias Hofving, Viktor Sandblom, Yvonne Arvidsson, Emman Shubbar, Gülay Altiparmak, John Swanpalmer, Bilal Almobarak, Anna-Karin Elf, Viktor Johanson, Erik Elias, Erik Kristiansson, Eva Forssell-Aronsson, and Ola Nilsson

. Hsp90 was overexpressed in neuroendocrine tumours In response to proteotoxic stressors, expression of heat shock proteins is upregulated to enable cell survival. Such stressors are usually prevalent in cancer cells, and Hsp90 inhibition has thus been

Free access

Anna Karpathakis, Martyn Caplin, and Christina Thirlwell

signalling pathways ( Karar & Maity 2011 ). Everolimus is approved for use in the treatment of clear cell renal cancer (when sunitinib therapy has failed) and giant cell astrocytoma. Initial trials of rapamycin and everolimus on neuroendocrine cell lines

Free access

Monica Ter-Minassian, Jennifer A Chan, Susanne M Hooshmand, Lauren K Brais, Anastassia Daskalova, Rachel Heafield, Laurie Buchanan, Zhi Rong Qian, Charles S Fuchs, Xihong Lin, David C Christiani, and Matthew H Kulke

Ellis LM Benedetti JK Bergsland EK Hobday TJ 2011 Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting . Journal of Clinical

Free access

Tanupriya Contractor, Richard Clausen, Grant R Harris, Jeffrey A Rosenfeld, Darren R Carpizo, Laura Tang, and Chris R Harris

Tentu R , 2013 The genomic landscape of small intestine neuroendocrine tumors . Journal of Clinical Investigation 2502 – 2508 . ( https://doi.org/10.1172/JCI67963 ) Baxter RC 2014 IGF binding proteins in cancer: mechanistic and clinical